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Abstract: Purpose: To describe the impact of fluorine (18F) - fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) in detecting primary tumor focus in our patient population who had 
histopathologically proven metastasis. 
Methods: 37 patients who underwent 18F-FDG PET/CT to detect primary tumor focus in our department were included in 
the study. The results of PET/CT and clinical follow-up data were reviewed retrospectively. PET/CT results were 
compared with histological analysis and/or clinical follow-up data. 
Results: Primary site of malignancy was correctly identified by PET/CT in 16 patients (16/37, 43%). Lung was the most 
common detected site (7/16). The mean SUV of metastatic tumor was higher than that of primary tumor. False positive 
and false negative results were obtained in 2 patients, respectively. In the remaining patients (17/37; 46%) the primary 
tumor was not localized by PET/CT. According to these results, the sensitivity and specificity of PET/CT were calculated 
as 89% and 90%, respectively. However, PET/CT scan determined additional metastatic focus and therapy management 
was changed (9/37, 24%). The primary focus was established in 4 of 8 (50%) patients with metastatic cervical 
adenopathy and in 12 of 29 (41%) patients with extra cervical metastases. 
Conclusions: 18F-FDG PET/CT can detect the primary tumor focus in about half of all patients with histopathologically 
proven metastases. In the remaining patients, it may contribute to therapy management by identifying additional foci.  
Keywords: Cancer of unknown primary, 18F-FDG, Positron emission tomography, Therapy management, 
Metastases. 
INTRODUCTION 
Cancer of unknown primary (CUP) is responsible for 
2-5% of all new diagnosed cancer cases in the world 
[1]. CUP is described as a disorder whose primary 
tumor can not be established in patients with tumor 
metastases detected histopathologically. Usually the 
detection of primary tumor is quite difficult and this 
situation makes it difficult for clinicians to choose a 
suitable approach to patients. 
Histopathological examinations of metastatic lesions 
frequently do not provide sufficient information about 
primary tumorsite [2]. Conventional diagnostic 
techniques (thoraco-abdomino-pelvic computed 
tomography (CT) and/or magnetic resonance imaging 
(MRI) and mammography in women) have also limited 
accuracy in detecting primary site of malignancy in 
CUP. In the literature, the success of conventional 
imaging modalities for the determination of primary site 
of malignancy is about 10-35%. Together with 
improvement of imaging techniques, the detection rate 
of primary tumoris increasing [3-5]. However, the 
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problem on detection of primary tumor still continues in 
most of cases because of microscopic primary tumor 
foci or angiogenetic incompetence of primary tumor 
which leads to marked apoptosis [4, 6]. Nowadays, 
Fluorine (18F) - fluorodeoxyglucose (FDG) positron 
emission tomography/computed tomography (PET/CT) 
is a common used imaging tool in oncologic patients 
[7]. In the literature, 18F-FDG PET/CT imaging has 
been recommended for searching primary focus in 
CUP [8-11]. 
The goal of this study is to describe the impact of 
18F-FDG PET/CT in detecting primary tumor focus in 
our patient population who had histopathologically 
proven metastasis. 
MATERIALS AND METHODS 
Patients 
A total of 37 patients who had histopathologically 
proven metastases (20 female, 17 male; mean age: 
58.4 ± 10.6; age range: 34 - 80 years) were included in 
this retrospective study. All patients had undergone 
18F-FDG PET/CT in our department. 18F-FDG PET/CT 
results are compared with histological analysis and/or 
clinical follow-up data. Patients have been followed-up 
44.6+3.8 months. 18F-FDG PET/CT imaging was 
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performed either before or after conventional imaging 
methods.  
18F-FDG PET/CT 
Informed consent was taken from patients before 
imaging. PET/CT images were acquired with Discovery 
ST PET/CT scanner (General Electric, Milwaukee, 
Wisconsin, USA). Patients were fasted at least 6 hours 
before scanning and blood glucose levels were 
checked before 18F-FDG injection. A nonionic, water-
soluble radiographic contrast medium was given to only 
patients with suspicion of abdominal malignancy. 
Intravenous contrast agent was not used. Patients 
were rested in a quiet room without administrating 
muscle relaxant during waiting period. Whole body 
PET/CT imaging was performed while patients were in 
supine position, from skull base to mid thighs. Images 
were obtained approximately 1 hour after an 
intravenous injection of 555 MBq of 18F-FDG. CT image 
was obtained from the integrated PET/CT scanner with 
the use of a standardized protocol involving 140 kV, 70 
mA, a tube rotation time of 0.5 s per rotation, a pitch of 
6 and a section thickness of 5 mm. Immediately after 
the CT part, PET images were acquired for 4 minutes 
per bed position. PET images were reconstructed using 
non-contrast CT data for attenuation correction. 
Image Analysis 
Whole body PET/CT images were interpreted by 
two experienced nuclear medicine physicians by 
consensus. Comparison was made between focus 
showing increased uptake and background/blood pool 
activity. Their anatomic confirmation was made with CT 
images. The criteria for malignancy were accepted as 
18F-FDG hypermetabolism at the site of pathological 
changes on CT or marked focal hypermetabolism at 
the physiological uptake sites. Maximum standardized 
uptake value (SUV) was calculated for all pathologic 
lesions 
Data Analysis 
When the detected primary site on 18F-FDG PET/CT 
confirmed histopathologically, these lesions were 
accepted true positive (TP). If findings were not 
confirmed histopathologically, they would be accepted 
false positive (FP). When primary site was not detected 
on 18F-FDG PET/CT and conventional diagnostic 
techniques, this was accepted true negative (TN). 18F-
Table 1: Histological Types and Localizations of Metastases of 37 Patients with Histopathologically Proven 
Metastasis 
Histological Types 
Localizations Epithelial Adenocarcinoma Undefined Total 
Lymph Nodes 8 5 2 15 (41%) 
Cervical LN 6  2 8 
Axillary LN 1 2  3 
Supraclavicular LN  1  1 
Mediastinal LN 1   1 
Abdominal LN  2  2 
Bone 1 1 6 8 (22%) 
Liver 3 2  5 
Intraabdominal Mass   2 2 
Fluid     
Peritoneal 1 1  2 
Pleural 1   1 
Brain 2   2 
Thyroid  1  1 
Ovary 1   1 
TOTAL 17 (46%) 10 (27%) 10 (27%) 100 (100%) 
LN: lymph node, Undefined metastases could not be described as epithelial or adenocarcinoma origin. 
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FDG PET/CT didn’t show any focus, but some foci 
were established histopathologically and the 
classification was accepted false negative (FN). If there 
was pathologic uptake in more than one region, it was 
defined as generalized disease.  
Statistical Analysis 
TP/FP and TN/FN results were described according 
to criterion mentioned above. Sensitivity, specificity, 
negative predictive value (NPV), positive predictive 
value (NPV) and accuracy were computed by use of 
above mentioned data. SPSS 19.0(SPSS Inc; Chicago, 
Illinois, USA) was used for describing statistics. 
RESULTS 
Thirty seven patients with histopathologically proven 
metastasis were evaluated. The localizations of 
metastasis were demonstrated on Table 1. Lymph 
nodes were the most common metastatic area (41%), 
especially in the cervical region. The second site of 
metastasis was bone. Although the histologic subtype 
could not be described in 10 cases, the most common 
detected histological subtype was epithelial tumor 
metastasis in 17 cases.  
18F-FDG PET/CT Findings 
The comparison of 18F-FDG PET/CT positive and 
negative findings and histopathological examination 
and/or clinical follow-up results were represented on 
Tables 2 and 3. 
Primary tumor was correctly identified by 18F-FDG 
PET/CT in 16patients (16/37, 43%). The primary sites 
of malignancy were lung in 7 patients, nasopharynx in 
3 patients, colon, thyroid, tongue, breast, GEP NET 
(gastroenteropancretic neuroendocrine tumor) and 
leukemia in each patient. The mean SUV of metastatic 
tumor was higher than that of primary tumor  
Table 2: The Comparison of 18F-FDG PET/CT Positive Results and Histopathological Analysis/Clinical Follow-Up Data 
Gender Age/Gender Metastatic Localizations (SUV max) Metastatic Histology 
18F-FDG PET/CT 
Results (SUV max) Gold Standard Accuracy 
1 45/M Bone (4.1) Malign tumor Bone marrow (4.4) T-cell leukemia TP 
2 59/M Servical LN (14.1) Malign epithelial tumor Nasopharynx (12.1) Nasopharyngeal Carcinoma TP 
3 45/F Brain (operated) Malign epithelial tumor Thyroid (4.7) Papillary Thyroid Carcinoma TP 
4 57/F Supraclaviculary LN (7.7) Adenocarcinoma metastasis Lung (5.4) Lung carcinoma TP 
5 55/F Axillary LN (11.5) Malign epithelial tumor Lung (15.5) Lung carcinoma TP 
6 64/F Mediastinal LN (9.1) Malign epithelial tumor Lung (8.1) Lung carcinoma TP 
7 69/M Bone  (21.3) Metastatic cancer Lung (21.0) Lung carcinoma TP 
8 49/F Servical LN (15.0) Undifferantiated tumor met. Nasopharynx (7.1) Nasopharyngeal Carcinoma TP 
9 56/F Liver (10.1) Adenocarcinoma metastasis Lung (5.1) Lung carcinoma TP 
10 61/M Servical LN (10.8) Undifferantiated tumor met. Tongue (9.5) Tongue cancer TP 
11 61/M Bone (15.6) Malign epithelial tumor Lung (4.7) Lung carcinoma TP 
12 57/M Brain (operated) Malign epithelial tumor Lung (16.1) Lung carcinoma TP 
13 73/F Peritoneal fluid (12.6) Adenocarcinoma metastasis Colon (19.8) Colon carcinoma TP 
14 42/M Intraabdominal mass Malign tumor Tongue (12.3) - FP 
15 55/F Liver (16.8) Adenocarcinoma metastasis Colon (5.0) - FP 
16 61/M Servical LN (13.9) Malign epithelial tumor Nasopharynx (8.6) Nasopharyngeal Carcinoma TP 
17 72/F Axillary LN (4.4) Adenocarcinoma metastasis Breast (2.5) Breast carcinoma TP 
18 34/F Liver (10.5) Malign epithelial tumor Jejenum (7.9) GEP NET TP 
18F-FDG PET/CT: 18Fluorine-fluorodeoxyglucose positron emission tomography/ computed tomography; LN: lymph node; TP: true positive; FP: 
false positive; GEP NET: gastroenteropancreatric neuroendocrine tumor. 
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(11.5 vs 8.6). Lung was the most common detected site 
for primary tumor. The mean SUV for primary lung 
carcinoma was 10.8. However the mean SUV of 
metastatic foci of primary lung carcinoma was 12.6. In 
the detailed analysis of histopathologic groups, the 
mean SUV of metastases was higher than that of 
primary tumor in both groups. Undefining histologic 
subtype group could not be evaluated. Due to the small 
number of histologic subtype, statistical analysis could 
not be performed.  
The findings of 18F-FDG PET/CT were concordant 
with histopathologic examination and/or clinical follow-
up results on 33/37 (89%) patients. The findings were 
TP in 16 (49%) and TN in 17 (51%) of them. While the 
stage was not changed in 8 of 19 cases in whom 
primary focus hasn’t been established, generalized 
disease was detected in 9 patients. 18F-FDG PET/CT 
results were normal in 2 patients also. According to 
this, 18F-FDG PET/CT had changed the therapy 
management in 9 of 32 patients. In 4 (11%) patients, 
18F-FDG PET/CT findings were discordant with 
histopathologic examination and/or clinical follow-up 
results. Two of them were FN and the others were FP 
findings. In one patient who had intraabdominal 
metastatic lymph nodes, 18F-FDGPET/CT could not 
localized primary site, but this patient was accepted as 
pancreatic cancer in the follow-up (FN). In other patient 
who had axillary metastatic lymph nodes, generalized 
disease was detected by 18F-FDG PET/CT. Breast 
carcinoma was accepted as primary site in the follow-
up (FN). In detailed analysis of FP findings, FDG 
uptakes in tongue (SUV:12.3) and colon (SUV:5.0) 
were seen in two patients. Focal increased uptake on 
tongue was accepted as physiologic in the follow-up. 
The histopathologic examination result of colon was 
polyp.  
When the findings were evaluated for the 
localization of metastatic foci, in 8 of 37 cases were 
metastatic cervicaladenopathy, and the rest was 
extracervical metastases. The primary focus was 
established by 18F-FDG PET/CT in 4 of 8(50%) patients 
with metastatic cervical adenopathy and in 12 of 
29(41%) patients with extracervical metastases.  
Table 3: The Comparison of 18F-FDG PET/CT Negative Results and Clinical/Gold Standard Findings 
Gender Age/Gender Metastatic Localizations Metastatic Histology 
18F-FDG PET/CT Results Gold Standard Accuracy 
1 40/F Bone  Metastatic cancer Bone metastases  - TN 
2 68/F Liver Malign epithelial tumor Generalized disease - TN 
3 50/F Bone Metastatic cancer Generalized disease - TN 
4 59/M Intraabdominal mass Metastatic cancer Normal - TN 
5 35/M Thyroid Adenocarcinoma metastasis Thyroid metastasis - TN 
6 37/F Ovary Malign epithelial tumor Normal - TN 
7 63/F Intraabdominal LN Adenocarcinoma metastasis Generalized disease - TN 
8 66/F Pleural fluid Malign epithelial tumor Pleural metastasis - TN 
9 58/M Bone Adenocarcinoma metastasis Generalized disease - TN 
10 66/M Servical LN Malign epithelial tumor Generalized disease - TN 
11 69/F Servical LN Malign epithelial tumor Lymphatic metastasis - TN 
12 59/F Bone Metastatic cancer Bone metastasis - TN 
13 63/M Intraabdominal LN Adenocarcinoma metastasis Lymphatic metastasis Pancreatic carcinoma FN 
14 58/M Servical LN Epithelial tumor metastasis Lymphatic metastasis - TN 
15 75/F Peritoneal fluid Epithelial tumor metastasis Peritoneal metastasis - TN 
16 80/M Liver Malign epithelial tumor Generalized disease - TN 
17 78/F Axillary LN Adenocarcinoma metastasis Generalized disease Breast carcinoma FN 
18 63/M Bone  Metastatic cancer Generalized disease - TN 
19 60/M Servical LN Epithelial tumor metastasis Generalized disease - TN 
18F-FDG PET/CT: 18Fluorine- fluorodeoxyglucose positron emission tomography/computed tomography; LN: lymph node; FN: false negative; 
TN: true negative. 
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The sensitivity and specificity of 18F-FDG PET/CT 
for detecting primary site were calculated 89% and 
90%, respectively. 
DISCUSSION 
CUP is a clinical process which makes up 2-5% of 
all new diagnosed cancers, including heterogeneous 
tumor groups, and which makes it difficult to establish 
the way to approach the patient. Detection of the 
primary focus in early period may help clinician by 
providing the use of a more specific and effective 
therapy method. For this reason, early detection of the 
primary focus and/or correct staging is an important 
point in approaching patients with CUP. 
The usefulness of conventional imaging methods 
establishing the primary focus is limited. In studies that 
have been done, the rate of success is between 10-
35% [3-5]. On the other hand, the studies with 18F-FDG 
PET/CT, it is emphasized that 18F-FDG PET/CT is a 
useful method in establishing in tumors with both 
metastatic cervical adenopathyand extracervical 
metastases [12-14]. According to our study, it has been 
found that primary focus could be establish in 50% of 
cases with metastatic cervical adenopathy and 41% of 
cases with extracervical metastases.  
The accuracy of 18F-FDG PET/CT on the detection 
of primary tumor site was reported between 24-63% in 
different studies [2, 5, 8-11, 15-16]. Many causes can 
lead to different results. Firstly, the patient populations 
of different studies are very heterogeneous. In addition, 
clinical examination and imaging tools may vary 
according to the centers. Clinic presentation of disease 
is very important especially patients with disseminated 
focus. The prediction of primary site is easier in 
patients with typical clinical presentation. In our study, 
18F-FDG PET/CT showed primary tumor focus in 16 
patients of total 37patients (43%). This rate is similar 
with literature. Generalized disease was established in 
9 of the cases after 18F-FDG PET/CT and PET/CT also 
added to change the therapy management in 9 of 37 
patients (24%). In the current literature, the sensitivity 
and specificity of 18F-FDG PET/CT in the search for the 
primary was reported as 62% and 82% respectively 
[10]. The sensitivity and specificity was calculated 89% 
and 90% in our study, respectively.  
During follow-up period, primary site could not be 
detected histopathologically in any patients without 
primary site on PET/CT. Only in two patients, primary 
tumor sites were accepted as clinically. It does not 
mean that primary site does not exist. In some cases 
18F-FDG PET/CT could not show the primary site 
because of physiological uptake sites or resolution 
limitation (such as microscopic primary tumor focus or 
low metabolic activity). The detection of primary tumor 
foci is get harder in tumors with high metabolic 
metastasis. The histologic grade of tumor varies the 
visibility of tumor on 18F-FDG PET/CT. In addition to, 
the cause of the problem on detection of primary tumor 
could be still continues in most of cases because of 
microscopic primary tumor foci or angiogenetic 
incompetence of primary tumor which leads to marked 
apoptosis. Because none of patients have died or 
suffered any serious complication related with 
malignancy in 18F-FDG PET/CT negative group during 
the follow-up period, the primary malignancies of these 
patients probably were well differentiated or low grade. 
This could be a reason for decreasing the success of 
18F-FDG PET/CT in this group. Nowadays, it seems 
that there is not more sensitive imaging tool in 18F-FDG 
PET/CT negative patient groups.  
Seve et al. [16] reported that the most common 
detected primary site was lung in patients with CUP. 
The most common detected primary site was lung also 
in our study in 7 patients (44%). When compare with 
the sites which have intense physiologic activity 
distribution such as gastrointestinal and genitourinary 
system, especially the detection of lung lesions larger 
than 1 cm is easier. In our study, 18F-FDG PET/CT 
imaging had been performed before conventional 
imaging methods in patients who had lung carcinoma. 
CT also could help to define the lung carcinoma in 
these patients. However, in clinical practice, whole 
body imaging with 18F-FDG PET/CT appears to be an 
easier but not excellent method to define primary site. 
The mean SUV of metastatic tumor was higher than 
that of primary tumor. That SUV was lower in primary 
tumor may be explained with necrosis of tumor in 
primary focus and poor differentiation of metastatic 
focus.  
Recently, anatomic and functional information has 
been obtained simultaneously by use of conventional 
systems that get PET and CT together. This shows that 
integrated PET/CT systems are more correct than P Et 
alone in evaluation of presents of tumor focus and 
localization. Despite of all these, physiological 
distribution areas (gastrointestinal uptake, urinary 
uptake, ovarian uptake, brain uptake vs) of 18F-FDG 
and processes of inflammation may cause false 
positive and negative results. In this study, there were 
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two false negative results. However, there were false 
positive findings (in tongue and colon), which has 
mimicking primary tumor focus in 2 cases. Focal 
increased uptake on tongue was accepted as 
physiologic in the follow-up. The histopathologic 
examination result of colon was polyp.  
Yaganawa et al. [17] reported that the difference 
between sensitivity of 18F-FDG PET and conventional 
imaging methods was not significant in patients with 
CUP. However, in that study most of patients had been 
evaluated by 18F-FDG PET instead of 18F-FDG 
PET/CT. In this patient group, PET/CT via to give both 
anatomic and metabolic information is more sensitive 
than PET. Garin et al. [18] published an article about 
the usefulness of 18F-FDG PET in CUP. They showed 
the accuracy for identification primary tumor by 
immunohistochemical profile of metastasis has much 
information about the primary as 18F-FDG PET. In our 
study, the immunohistochemical examination has not 
been performed routinely, so we did not compare the 
immunohistochemical examination and 18F-FDG 
PET/CT. 
CONCLUSION 
In this retrospective analysis we concluded that 18F-
FDG PET/CT can detect the primary tumor focus in 
about half of all patients with histopathologically proven 
metastases. In the remaining patients, it may contribute 
to therapy management by identifying additional foci. 
Despite the relatively low number of patients, the 
sensitivity of 18F-FDG PET/CT seems to be unaffected 
by the presence of cervical or extracervical metastases 
in clinical presentation.  
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